<DOC>
	<DOCNO>NCT02144038</DOCNO>
	<brief_summary>This Phase Ib/II study primary purpose Phase Ib part estimate MTD and/or recommend phase 2 dose ( RP2D ) combination LGH447 BYL719 administer orally adult patient relapse refractory multiple myeloma . Once MTD and/or RP2D determine combination LGH447 BYL719 , additional patient enrol Phase II part determine whether combination LGH447 BYL719 exhibit improve anti-multiple myeloma activity compare single agent LGH447 .</brief_summary>
	<brief_title>Study Safety Effectiveness LGH447 BYL719 Patients With Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Patients confirm diagnosis multiple myeloma receive two line therapy refractory recent line therapy , define relapse therapy within 60 day last line therapy . If patient receive either immunomodulatory drug ( IMID ) proteasome inhibitor prior therapy Investigator must notify Novartis prior patient enrollment . Patients receive prior bone marrow transplant otherwise meet inclusion criterion eligible study For patient Phase II portion study , must measurable disease define least 1 follow 3 measurement : Serum Mprotein ≥ 0.5 g/dL Urine Mprotein ≥ 200 mg/24 hour OR Serum free light chain ( FLC ) &gt; 100 mg/L involve FLC All patient must willing undergo mandatory bone marrow aspirate and/or biopsy baseline assessment biomarker/pharmacodynamics disease status Systemic antineoplastic therapy ( include unconjugated therapeutic antibody toxin immunoconjugates ) experimental therapy within 14 day 5 halflives , whichever short , first dose either study drug Radiotherapy within 14 day first dose either study drug except localize radiation therapy lytic bone lesion plasmacytomas Major surgery within 2 week first dose either study drug Ongoing therapy chronic high dose corticosteroid . Low dose steroid ( i.e . prednisone ≤ 10 mg equivalent steroid dose ) , inhaled topical steroid permit Patients currently receive treatment prohibit medication discontinue least one week prior start treatment : Narrow Therapeutic index substrate , strong inhibitor strong inducer CYP3A4 Strong Inhibitors CYP2D6 Narrow therapeutic index substrate CYP2C8 , CYP2C9 , CYP2C19 CYP2D6 Any follow clinical laboratory result screen ( i.e. , within 28 day first dose either study drug ) : Absolute neutrophil count ( ANC ) &lt; 1,000/mm3 without growth factor support within 7 day prior test Platelet count &lt; 75,000 mm3 without transfusion support within 7 day prior test Bilirubin &gt; 1.5 time upper limit normal range ( ULN ) . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 3 time ULN . Calculated creatinine clearance &lt; 30 ml/min accord CockcroftGault equation Corrected QT interval ( QTc ) &gt; 450 millisecond ( m ) males &gt; 470 millisecond ( m ) females baseline electrocardiogram ( ECG ) ( use Fridericia [ QTcF ] correct QT interval</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>multiple myeloma ,</keyword>
	<keyword>relapsed refractory ,</keyword>
	<keyword>LGH447 ,</keyword>
	<keyword>pan-PIM inhibitor ,</keyword>
	<keyword>PIM Kinase ,</keyword>
	<keyword>BYL719 ,</keyword>
	<keyword>PI3K inhibitor</keyword>
</DOC>